1. Home
  2. NVNI vs NOTV Comparison

NVNI vs NOTV Comparison

Compare NVNI & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$3.67

Market Cap

57.2M

Sector

N/A

ML Signal

HOLD

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.85

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVNI
NOTV
Founded
2019
1974
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.2M
29.9M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
NVNI
NOTV
Price
$3.67
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
162.1K
1.6M
Earning Date
09-30-2025
12-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,250,627.00
$513,024,000.00
Revenue This Year
$12.05
$6.26
Revenue Next Year
$15.02
$45.49
P/E Ratio
N/A
N/A
Revenue Growth
1491.58
4.54
52 Week Low
$1.44
$0.66
52 Week High
$121.90
$6.48

Technical Indicators

Market Signals
Indicator
NVNI
NOTV
Relative Strength Index (RSI) 59.57 40.34
Support Level $3.32 $0.79
Resistance Level $3.00 $0.95
Average True Range (ATR) 0.32 0.08
MACD 0.09 0.02
Stochastic Oscillator 63.70 42.76

Price Performance

Historical Comparison
NVNI
NOTV

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: